Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Checa 2,3 , K
Retatrutide: The First-of-its-Kind Triple Receptor Agonist Retatrutide is a leading triple-receptor agonist that simultaneously activates three key metabolic receptors: GLP-1, GIP, and GCGR
Many patients experience an average weight loss of 10% to 18% of their starting body weight, and some lose 15% to 21% of their body weight over 68 weeks, depending in part on starting weight
Patients should not be overly concerned or discontinue their medication without consulting their physician
Between Q4 2024 and Q1 2025, the share of Medicare patients with comorbid diabetes or obesity and MASLD who started a GLP1 rose from 13% to 19%, compared with only a modest increase from 20% to 22% among commercially insured patients
Avoid non-breathable synthetics
US$ 21.98
US$ 28.51
US$ 23.86
US$ 27.09
US$ 25.13
